ShangBay Capital LLC — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Window Therapeutics develops cancer therapeutics using its proprietary Bottle-brush-Analogue-Macromonomer (BAM) technology, which aims to widen the therapeutic window of drugs by increasing their activity against cancer cells while reducing systemic toxicity to healthy tissue.
BiotechDeep TechHealthtechBoston, US
James Lu(Director)Jeremiah Johnson(Director)Lusong Luo(Director)Kenneth Anderson(Director)Chih-Kao Hu(Executive Officer, Director)Kenneth C. Anderson(Professor, Researcher and Clinician, Harvard Medical School & DFCI)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.